These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39002694)

  • 1. Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment.
    Yang C; Deng X; Tang Y; Tang H; Xia C
    Cancer Lett; 2024 Aug; 598():217116. PubMed ID: 39002694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients.
    Devarajan N; Manjunathan R; Ganesan SK
    Crit Rev Oncol Hematol; 2021 Jun; 162():103327. PubMed ID: 33862250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma.
    Wei Z; Yin X; Cai Y; Xu W; Song C; Wang Y; Zhang J; Kang A; Wang Z; Han W
    Int J Nanomedicine; 2018; 13():1505-1524. PubMed ID: 29559779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
    Chen SH; Chang JY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in hypoxia.
    Chen Y; Fang L; Zhou W; Chang J; Zhang X; He C; Chen C; Yan R; Yan Y; Lu Y; Xu C; Xiang G
    J Nanobiotechnology; 2021 Aug; 19(1):246. PubMed ID: 34399762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorescence monitoring of hypoxic microenvironment in solid-tumors to evaluate chemotherapeutic effects using the hypoxia-sensitive iridium (III) coordination compound.
    Zeng Y; Liu Y; Shang J; Ma J; Wang R; Deng L; Guo Y; Zhong F; Bai M; Zhang S; Wu D
    PLoS One; 2015; 10(3):e0121293. PubMed ID: 25786221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
    Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
    Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diverse effects of cisplatin on tumor microenvironment: Insights and challenges for the delivery of cisplatin by nanoparticles.
    Meng X; Ma F; Yu D
    Environ Res; 2024 Jan; 240(Pt 1):117362. PubMed ID: 37827371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
    Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
    J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
    Pastorek M; Simko V; Takacova M; Barathova M; Bartosova M; Hunakova L; Sedlakova O; Hudecova S; Krizanova O; Dequiedt F; Pastorekova S; Sedlak J
    Int J Oncol; 2015 Jul; 47(1):51-60. PubMed ID: 25955133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
    Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS
    Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.
    Li W; Sun X
    Recent Pat Anticancer Drug Discov; 2018; 13(4):455-468. PubMed ID: 30173649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research Progress in Reversal of Tumor Multi-drug Resistance via Natural Products.
    Guo Q; Cao H; Qi X; Li H; Ye P; Wang Z; Wang D; Sun M
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1466-1476. PubMed ID: 29034843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy.
    Dasari S; Njiki S; Mbemi A; Yedjou CG; Tchounwou PB
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-mediated cancer stem cell resistance and targeted therapy.
    Sun X; Lv X; Yan Y; Zhao Y; Ma R; He M; Wei M
    Biomed Pharmacother; 2020 Oct; 130():110623. PubMed ID: 32791395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
    Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
    Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.